# Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

> **NCT03202758** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centre Georges Francois Leclerc** · enrollment: 57 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Durvalumab, Tremelimumab and ,FOLFOX

## Key facts

- **NCT ID:** NCT03202758
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-29
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202758, "Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03202758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*